Market Overview –
The Global Animal Auto-Immune Disease Diagnostics Market is a condition in which the immune system fails to recognise the body’s tissues as foreign antigens and begins to attack and reject them. Allergies (a hypersensitive immune system) and autoimmune diseases of the skin are among the most common autoimmune conditions in animals. Pemphigus vulgaris, Autoimmune hemolytic anaemia (AIHA), dry eye, Addison’s disease and others are among the most common autoimmune diseases in animals.
The absolute measurement of blood panel to analyse the red blood cell, platelet, and blood cortisol is used to diagnose autoimmune disease in animals, particularly in companion animals. These tests are useful for determining whether a blood sample contains positive anti-nuclear antibodies. Urinalysis and thyroid tests are used by veterinarians to diagnose autoimmune disease in animals. T3 (triodothyronine) and T4 (levothyroxine) and other antibodies that indicate auto-immune thyroiditis and other forms of genetic diseases are examined in the most recent thyroid tests.
COVID-19 Impact –
The COVID-19 pandemic has wreaked havoc across the globe, affecting all sectors of the economy. Similarly, the market for diagnosing animal auto-immune diseases is expected to suffer. Now the target industry has to deal with managing the interrupted supply and demand for components. The target industry’s growth is also expected to be hampered by unpredictability in the supply chain and a shortage of human resources.
The rising number of zoonotic infections like SARS-CoV-2 aka Covid-19 is expected to have an effect on the global market for animal auto-immune disease diagnostics. The target industry is expected to grow faster than the overall economy over the next few years due to an increase in animal health spending.
Market Opportunities –
China and India, two fast-growing economies, present lucrative business opportunities for the world’s leading players in the field of animal auto-immune disease diagnostics. Asian and African markets are seeing an increase in the use of animal healthcare services, particularly for livestock, as demand for meat and other animal products in the cosmetic and pharmaceutical industries continues to rise. The growing accessibility of veterinary care facilities that link human and pet health issues is another way to raise awareness about the risk of transmission of zoonotic diseases.
Recent Development –
It was in October of this year that AVISE CTD and AVISE Lupus were added to the Inland Empire Health Plan’s (IEHP) list of approved autoimmune testing services, allowing 1.4 million members to receive better care. AVISE diagnostic testing is now available as an in-network benefit under the terms of the agreement.
To better serve patients with autoimmune diseases, Exagen Inc. announced in January 2021 that it had signed a contract with Tufts Medical Center, an internationally renowned academic medical centre, to provide all AVISE test offerings as an in-network service. This includes the CTD and Lupus AVISE tests, the SLE Prognostic AVISE tests and the APS AVISE tests.
Scope of the Report –
When an organism produces an abnormal immune response to its own tissue, autoimmunity is defined by the report’s scope. Self-reactive T cells, autoantibodies, and inflammation are all hallmarks of autoimmune disease. This complicates the diagnosis of possible autoimmune disorders, as not all tests can be used to make a diagnosis. When it comes to treating patients with autoimmune diseases and determining their prognosis or the extent of organ damage, a diagnosis can be an invaluable tool.
Disease Type (Rheumatoid Arthritis, Psoriasis, Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, and Other Systemic Autoimmune Diseases) and Localized Autoimmune Disease (Inflammatory Bowel Disease, Type 1 Diabetes, Thyroid, and Other Localized Autoimmune Diseases) segment the Autoimmune Disease Diagnostics Market. Diagnosis Type (Antinuclear Antibody Tests (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The value (USD million) of the above segments is included in the report.
Competitive Landscape –
Anti-inflammatory disease diagnostics is a crowded and competitive field. Research and development and effective growth strategies are being pursued by the major market players in the market. A small number of diagnostic companies have recently formed strategic alliances with medical facilities. In order to meet the increasing demands of patients in different regions, this trend is expected to continue for the foreseeable future.
The following manufacturers are covered –
Mindray Medical International Ltd
Elabscience Biotechnology Co. Ltd.
Thermo Fisher Scientific
By Type –
By Applications –
By Regions –